DOSE Stock Overview
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada.
Rapid Dose Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.10|
|52 Week High||CA$0.69|
|52 Week Low||CA$0.08|
|1 Month Change||-50.00%|
|3 Month Change||-65.52%|
|1 Year Change||-83.33%|
|3 Year Change||-85.91%|
|5 Year Change||n/a|
|Change since IPO||-88.24%|
Recent News & Updates
|DOSE||CA Life Sciences||CA Market|
Return vs Industry: DOSE underperformed the Canadian Life Sciences industry which returned -21.3% over the past year.
Return vs Market: DOSE underperformed the Canadian Market which returned -1.7% over the past year.
|DOSE Average Weekly Movement||29.4%|
|Life Sciences Industry Average Movement||11.6%|
|Market Average Movement||10.9%|
|10% most volatile stocks in CA Market||19.4%|
|10% least volatile stocks in CA Market||4.4%|
Stable Share Price: DOSE is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 29% a week.
Volatility Over Time: DOSE's weekly volatility has increased from 18% to 29% over the past year.
About the Company
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries.
Rapid Dose Therapeutics Fundamentals Summary
|DOSE fundamental statistics|
Is DOSE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DOSE income statement (TTM)|
|Cost of Revenue||CA$283.05k|
Last Reported Earnings
Nov 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.019|
|Net Profit Margin||-195.24%|
How did DOSE perform over the long term?See historical performance and comparison
Is DOSE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DOSE?
Other financial metrics that can be useful for relative valuation.
|What is DOSE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does DOSE's PS Ratio compare to its peers?
|DOSE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
IPA ImmunoPrecise Antibodies
GRIN Grown Rogue International
AYUR Ayurcann Holdings
DOSE Rapid Dose Therapeutics
Price-To-Sales vs Peers: DOSE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the peer average (3.2x).
Price to Earnings Ratio vs Industry
How does DOSE's PE Ratio compare vs other companies in the North American Life Sciences Industry?
Price-To-Sales vs Industry: DOSE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the North American Life Sciences industry average (5.3x)
Price to Sales Ratio vs Fair Ratio
What is DOSE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||10.1x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate DOSE's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of DOSE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DOSE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DOSE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Rapid Dose Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rapid Dose Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Rapid Dose Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Rapid Dose Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Rapid Dose Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DOSE is currently unprofitable.
Growing Profit Margin: DOSE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DOSE is unprofitable, but has reduced losses over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare DOSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DOSE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.5%).
Return on Equity
High ROE: DOSE has a negative Return on Equity (-58.49%), as it is currently unprofitable.
Discover strong past performing companies
How is Rapid Dose Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DOSE's short term assets (CA$1.1M) do not cover its short term liabilities (CA$1.9M).
Long Term Liabilities: DOSE's short term assets (CA$1.1M) exceed its long term liabilities (CA$443.9K).
Debt to Equity History and Analysis
Debt Level: DOSE's net debt to equity ratio (14.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if DOSE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DOSE has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: DOSE is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
What is Rapid Dose Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DOSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DOSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DOSE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DOSE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DOSE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. since May 03, 2017 and he serves as its Chairman. He served as President of Rapid Dose Therapeutics Corp...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD77.59K) is below average for companies of similar size in the Canadian market ($USD186.69K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Experienced Management: DOSE's management team is considered experienced (3.9 years average tenure).
Experienced Board: DOSE's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Rapid Dose Therapeutics Corp.'s employee growth, exchange listings and data sources
- Name: Rapid Dose Therapeutics Corp.
- Ticker: DOSE
- Exchange: CNSX
- Founded: NaN
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$10.533m
- Shares outstanding: 105.33m
- Website: https://www.rapid-dose.com
- Rapid Dose Therapeutics Corp.
- 1121 Walkers Line
- Unit 3A
- L7N 2G4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/05 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.